Sirolimus-eluting stents: A review of experimental and clinical findings

Konstantinos Toutouzas, Carlo Di Mario, Robert Falotico, Takuro Takagi, Goran Stankovic, Remo Albiero, Nicola Corvaja, Antonio Colombo

Research output: Contribution to journalArticlepeer-review

Abstract

Sirolimus (rapamycin), a macrolide antibiotic with known potent immunosuppressive properties, acts in the first phase (G1) of the cell cycle, blocking its further progression to the phase of DNA synthesis (S). In experimental models, rapamycin is effective in inhibiting smooth muscle cell proliferation and migration after vessel wall injury with balloon angioplasty. These results lead to the clinical application of sirolimus-eluting stents in 45 patients in Sao Paulo and Rotterdam (FIM Registry) and 238 patients in a randomized, European multicenter trial (RAVEL). These trials showed, by angiography and intravascular ultrasound, almost complete abolition of in-stent late hyperplasia up to one year after the procedure. In this review, we describe the experimental and clinical results of sirolimus-eluting stents including our experience of 26 stents implanted in 17 patients. In elective de novo lesions has shown remarkably clear lumens at follow-up angiography and intravascular ultrasound within the stented segments were observed with no lesion progression at the stent margins or thrombosis after a 2 month regimen of aspirin, and ticlopidine or clopidogrel. New large-scale ongoing clinical trials will investigate the efficacy of sirolimus-eluting stentsin lesions that are traditionally associated with high restenosis rates after stent implantation, such as long lesions, bifurcations and instent restenosis.

Original languageEnglish
Pages (from-to)49-57
Number of pages9
JournalZeitschrift fur Kardiologie
Volume91
Issue numberSUPPL. 3
DOIs
Publication statusPublished - 2002

Keywords

  • FIM
  • Rapamycin
  • RAVEL
  • Restenosis
  • Sirolimus
  • Stent

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Sirolimus-eluting stents: A review of experimental and clinical findings'. Together they form a unique fingerprint.

Cite this